BioLife Solutions (BLFS) Refocuses on Cell Processing After Evo Sale—Is Its Core Platform Ready to Scale?

• BioLife Solutions, Inc. recently reported third-quarter 2025 results, posting US$28.07 million in revenue and earnings of US$0.01 per share, both of which surpassed analyst expectations following the sale of its evo cold chain logistics segment.
• This shift enables BioLife Solutions to focus on accelerating growth in its core cell processing platform, which has seen strong recurring demand and expanded market share.
• We will examine how the updated 2025 revenue guidance, raised after the business divestiture, may shape BioLife’s investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

BioLife Solutions Investment Narrative Recap

To own shares of BioLife Solutions, you need to believe in the expanding adoption of advanced cell and gene therapies, with BioLife’s core cell processing platform benefiting from continued momentum and integration into clinical workflows. The company’s third-quarter results, which beat revenue and earnings expectations, support enthusiasm around recurring demand, but also shine a light on key risks such as heavy reliance on a concentrated customer base, which could drive earnings volatility if large clients reduce orders. The recent news significantly reinforces the short-term catalyst of recurring revenue growth, while the customer concentration risk remains an important consideration for shareholders.

BioLife’s updated 2025 revenue guidance, projecting 27% to 29% year-over-year growth after the divestiture of evo cold chain logistics, stands out in the context of this earnings beat. With cell processing platform revenue targets raised to US$93.0 million to US$94.0 million, the company appears to be capitalizing on higher recurring demand within its core business segment, a factor closely watched by investors looking for clear growth levers and operational focus.

However, while the growth outlook excites, investors should also be alert to the less visible risk if one of BioLife’s largest customers decides to...

Read the full narrative on BioLife Solutions (it's free!)

BioLife Solutions' narrative projects $161.3 million revenue and $33.2 million earnings by 2028. This requires 19.9% yearly revenue growth and a $52.1 million increase in earnings from -$18.9 million today.

Uncover how BioLife Solutions' forecasts yield a $31.30 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community valued BioLife Solutions between US$10.69 and US$38.66 per share ahead of this news. In contrast, recurring revenue growth and customer concentration could have outsized effects on future performance, highlighting why it pays to consider multiple perspectives.

Explore 4 other fair value estimates on BioLife Solutions - why the stock might be worth less than half the current price!

Build Your Own BioLife Solutions Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BioLife Solutions research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BioLife Solutions research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioLife Solutions' overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com